| Gilteritinib studied in …STUDIED_INderived58 of 58show fewer |
|---|
| → studied in | NCT05564390Phase 2 · recruiting MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) · 58 trials list this drug (32 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07140016Phase 1 · recruiting A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) · 58 trials list this drug (32 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03182244Phase 3 · completed A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06317649Phase 2 · recruiting Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04293562Phase 3 · recruiting A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05955261Phase 2 · recruiting A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05520567Phase 1/Phase 2 · active not recruiting A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07032727Phase 2 · recruiting Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations · 58 trials list this drug (32 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06235801Phase 1/Phase 2 · recruiting A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010122Phase 1/Phase 2 · recruiting ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · 58 trials list this drug (32 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03013998Phase 2/Phase 3 · recruiting Study of Biomarker-Based Treatment of Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05546580Phase 1 · active not recruiting Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06001788Phase 1 · recruiting Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Leukemia,Acute Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07131059NA · recruiting MRD-positive AML Clinical Study · 58 trials list this drug (32 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06265545NA · recruiting Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548710Phase 2 · recruiting Study of SA+X in the Treatment of Newly Diagnosed AML · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03836209Phase 2 · completed Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010772Phase 1 · recruiting Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02752035Phase 3 · completed A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06225427Phase 1 · recruiting Gilteritinib for the Treatment of ALK NSCLC · 58 trials list this drug (32 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756777Phase 1 · recruiting A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06992934NA · not yet recruiting Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors · 58 trials list this drug (32 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02115295Phase 2 · recruiting Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Myelodysplastic Syndrome,Secondary Acute Myeloid Leukemia,Acute Myeloid Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06222580Phase 1 · recruiting SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia,Acute Myeloid Leukemia with KMT2A Rearrangement,Acute Myeloid Leukemia with NPM1 Mutation+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04140487Phase 1/Phase 2 · recruiting Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm · 58 trials list this drug (32 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04988555Phase 1/Phase 2 · recruiting A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) · 58 trials list this drug (32 active) | — | — | Leukemia,Multiple Myeloma,Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07463651Phase 3 · recruiting MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07425808Phase 2/Phase 3 · not yet recruiting FLT3-ITD Targeted Therapy in Fit AML Patients · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04240002Phase 1/Phase 2 · terminated A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05024552Phase 1 · recruiting Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia with FLT3/ITD Mutation | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02421939Phase 3 · completed A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation · 58 trials list this drug (32 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06734585completed Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02310321Phase 1/Phase 2 · completed A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06696183Phase 2 · recruiting Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06022003Phase 2 · recruiting Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667973Phase 2 · not yet recruiting Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02997202Phase 3 · completed A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04027309Phase 3 · active not recruiting A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia,Myelodysplastic Syndrome/Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02014558Phase 1/Phase 2 · completed Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03730012Phase 1/Phase 2 · completed A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02495233Phase 1/Phase 2 · terminated A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) · 58 trials list this drug (32 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927262Phase 2 · completed A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02561455Phase 1/Phase 2 · completed Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial · 58 trials list this drug (32 active) | — | — | Solid Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02181660Phase 1 · completed Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02236013Phase 1 · completed A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02456883Phase 1 · completed Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors · 58 trials list this drug (32 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05177731Phase 3 · active not recruiting Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML · 58 trials list this drug (32 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06221683Phase 2 · recruiting Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia,Childhood Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05028751Phase 1/Phase 2 · terminated A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04336982Phase 1 · terminated A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05330377Phase 1 · withdrawn GM-CLAG in Relapsed/Refractory FLT3-mutated AML · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05791890unknown GilteRInf 2022 Study (Gilteritinib Related Infections) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05312112unknown Real World Outcomes Using Novel Agents for AML in the UK · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05279859Phase 1/Phase 2 · withdrawn A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655391Phase 1 · withdrawn Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625505Phase 1 · completed A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03070093approved for marketing Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03409081no longer available Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) · 58 trials list this drug (32 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |